Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD133 is an investigated surface marker for cancer stem-like cells (CSCs) that may be involved in tumor initiation in head and neck carcinomas.
|
29909565 |
2019 |
Tumor Initiation
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The ZnAs@SiO<sub>2</sub> NPs also inhibited tumor spheroid formation <i>in vitro</i> and tumor initiation <i>in vivo</i> and induced significant changes in the expression of stemness markers (CD133, Sox-2, and Oct-4) and EMT markers (E-cadherin, Vimentin, and Slug) both <i>in vitro</i> and <i>in vivo.</i> These effects of ZnAs@SiO<sub>2</sub> that correlated with prognosis of HCC were mediated by the SHP-1/JAK2/STAT3 signaling.
|
31285768 |
2019 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD133 is a widely used cell surface marker of cancer stem cells that plays an important role in tumor initiation and metastasis.
|
30873590 |
2019 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Their characteristics were investigated through colony formation, spheres formation, chemoresistance, flow cytometry for putative stem cell markers, such as CD133, CD34 and CD45, immunofluorescence staining and tumor initiation capacity <i>in vivo</i>.
|
29887968 |
2018 |
Tumor Initiation
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Knocking down OPN significantly inhibited the sphere formation and stemness-related genes expression, and delayed tumor initiation of CD133+/CD44+ subgroup of HCC cells.
|
30064482 |
2018 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD133 (Prominin-1), a stem cell marker implicated in tumor initiation, differentiation and resistance to anti-cancer therapy, is reportedly associated with EVs in various types of cancer.
|
28452069 |
2017 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In tumorigenesis, NCAM1(+)CD133(-) marks SIX2(+) blastema that includes the ALDH1(+) WT cancer stem/initiating cells, while NCAM1(+)CD133(+) and NCAM1(-)CD133(+) specifying early and late epithelial differentiation, are severely restricted in tumor initiation capacity and tumor self-renewal.
|
27020553 |
2016 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Among the biomarkers of CSCs, CD-133 (prominin-1) has been known to effectively isolate CSCs from cancer population, including GBM; however, the underlying mechanism of how stemness genes manipulate CSC-associated phenotypes, such as tumor initiation and relapse, is still unclear.
|
27530866 |
2016 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD133(+) cells demonstrated a trend for increased tumor initiation while CD24(+) cells versus CD24(-) cells had significantly greater tumor initiation and tumor growth capacity.
|
25969154 |
2015 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD133(+) cells possess strong tumorigenicity, responsible for tumor initiation and maintenance.
|
24271022 |
2013 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD133 is a marker that identifies/enriches cancer stem cell implicated in tumor initiation.
|
23408993 |
2013 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor cell subpopulations that express cancer stem cell markers such as CD133 (prominin1) or ABCB5 are thought to be crucial for tumor initiation and heterogeneity, but their biological significance in melanoma has been controversial.
|
22865455 |
2012 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings either imply that (i) AC133-positive and AC133-negative glioma cells comprise different, independent CSC populations, (ii) AC133-positive glioma cells are derived from primordial AC133-negative CSCs or (iii) AC133-negative CSCs have lost AC133 expression, while retaining their stem-like features and tumor initiation capacity, and can reacquire AC133 expression in vivo.
|
20853315 |
2011 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition to in vitro studies, in vivo tumor initiation experiments confirmed that CD133-sorted cells implanted into the flanks of nude mice grew faster and larger than unsorted cells.
|
21862685 |
2011 |
Tumor Initiation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Most important, TGFbeta1-induced CD133+ Huh7 cells demonstrate increased tumor initiation in vivo.
|
20196115 |
2010 |